Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2967/jnumed.117.197996 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Localized In Vivo Prodrug Activation Using Radionuclides.
J Nucl Med
January 2025
Center for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts;
Radionuclides used for imaging and therapy can show high molecular specificity in the body with appropriate targeting ligands. We hypothesized that local energy delivered by molecularly targeted radionuclides could chemically activate prodrugs at disease sites while avoiding activation in off-target sites of toxicity. As proof of principle, we tested whether this strategy of radionuclide-induced drug engagement for release (RAiDER) could locally deliver combined radiation and chemotherapy to maximize tumor cytotoxicity while minimizing off-target exposure to activated chemotherapy.
View Article and Find Full Text PDFSemi-standardized evaluation of extraprostatic extension and seminal vesicle invasion with [F]PSMA-1007 PET/CT: a comparison to MRI using histopathology as reference.
EJNMMI Rep
January 2025
Department of Translational Medicine, Lund University, Lund, Sweden.
Background: Positron emission tomography/computed tomography (PET/CT) with prostate specific membrane antigen ligands (PSMA) is established for use in primary staging of prostate cancer to screen for metastases. It has also shown promise in local tumor staging, including detection of extraprostatic extension (EPE) and seminal vesicle invasion (SVI). Previous studies have shown high heterogeneity in methods and results.
View Article and Find Full Text PDFUtility of Multiparametric Prostate MRI to Predict Regional or Distant Metastatic Disease Against Conventional Staging Using CT and Bone Scintigraphy or 68Ga-PSMA PET in Intermediate-to-High-Risk Prostate Cancer.
Cureus
November 2024
Department of Urology, Western Health, Melbourne, AUS.
Background: Multiparametric magnetic resonance imaging (mpMRI) is now the standard of care to guide prostate biopsies during workups and assessment of men with suspected prostate cancer (PCa). In addition to intraprostatic lesion detection, MRI usually covers the bony pelvis and pelvic lymph nodes, two of the commonest sites for metastatic disease. Subsequent staging has traditionally been based on further scanning using a combination of computed tomography (CT) and bone scintigraphy (BS), and more recently, positron emission tomography (PET) scanning with prostate-specific membrane antigen (PSMA) ligand.
View Article and Find Full Text PDFPSMA - Targeted Clinical Molecular Imaging of Atherosclerosis: Correlation with Cardiovascular Risk Factors.
Nuklearmedizin
December 2024
Department of Nuclear Medicine, University Medicine Göttingen, Georg-August-University Göttingen, Göttingen, Germany.
Aim: The early diagnosis of atherosclerotic changes to prevent ischemic events represents a clinical challenge.Prostate-specific membrane antigen (PSMA) as an established diagnostic in the field of prostate cancer also appears to detect neovascularization and inflammation in other diseases. We hypothesized that it might be also suited for detection of inflammation in atherosclerosis.
View Article and Find Full Text PDFFirst-in-human administration of [Tb]Tb-SibuDAB and comparative dosimetry with standard [Lu]Lu-PSMA-I&T as part of the PROGNOSTICS phase Ia study.
Eur J Nucl Med Mol Imaging
December 2024
PSI Center for Life Sciences, Villigen-PSI, Canton of Aargau, Switzerland.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!